株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

滲出性黄斑変性症および新生血管黄斑変性症:世界の治験動向

Wet (Neovascular / Exudative) Macular Degeneration Global Clinical Trials Review, H2, 2016

発行 GlobalData 商品コード 339391
出版日 ページ情報 英文 259 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.40円で換算しております。
Back to Top
滲出性黄斑変性症および新生血管黄斑変性症:世界の治験動向 Wet (Neovascular / Exudative) Macular Degeneration Global Clinical Trials Review, H2, 2016
出版日: 2016年12月21日 ページ情報: 英文 259 Pages
概要

当レポートでは、滲出性黄斑変性症および新生血管黄斑変性症の治験 (臨床試験) に関する最新動向について分析しており、地域別の治験件数、治験の段階別進行状況、被験者採用の状況、有望なスポンサー、各企業や研究機関における研究の進行状況、有望な薬剤の比較といった情報をまとめています。

イントロダクション

  • 滲出性黄斑変性症および新生血管黄斑変性症
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要5カ国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:眼科疾患治療薬の治験における滲出性黄斑変性症および新生血管黄斑変性症の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:眼科疾患治療薬の治験における滲出性黄斑変性症および新生血管黄斑変性症の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

滲出性黄斑変性症および新生血管黄斑変性症治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験のプロファイル

  • 主要企業の治験の概要
    • Novartis AG
    • Bayer AG
    • F. Hoffmann-La Roche Ltd.
    • Regeneron Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Ophthotech Corp.
    • Alcon, Inc.
    • Allergan Plc
    • Valeant Pharmaceuticals International, Inc.
    • Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
  • 代表的な研究機関・病院の治験の概要
    • Medical University of Vienna
    • National Eye Institute
    • University Health Network
    • Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
    • Azienda Ospedaliera Universitaria Integrata Verona
    • Het Oogziekenhuis Rotterdam
    • Oregon Health & Science University
    • Oslo University Hospital
    • Retina Institute of Hawaii
    • University of Miami

5つの代表的な治験のプロファイル

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC4024CTIDB

GlobalData's clinical trial report, "Wet (Neovascular / Exudative) Macular Degeneration Global Clinical Trials Review, H2, 2016" provides an overview of Wet (Neovascular / Exudative) Macular Degeneration clinical trials scenario. This report provides top line data relating to the clinical trials on Wet (Neovascular / Exudative) Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Wet (Neovascular / Exudative) Macular Degeneration
      • Oct 31, 2016: Ophthotech Announces the Publication of Fovista in Combination with Lucentis Phase 2b Study Results in Ophthalmology, the Journal of the American Academy of Ophthalmology
      • Oct 10, 2016: Oxford BioMedica Announces Publication of Pioneering RetinoStat (OXB-201) Phase I Study Data in the Journal, Human Gene Therapy
      • Sep 30, 2016: Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
  • Source

List of Tables

  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Region, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top